| Objectives:To detect the peripheral blood levels of Myeloperoxidase(MPO) and N-terminal pro-brain natriuretic peptide(NT-proBNP)in patients with acute coronary syndromes and follow-up cardiovascular events,and then to explore the clinical value of combined assay of peripheral blood MPO and NT-proBNP in prognosis evaluation.Methods:77 patients were choosed according to patient history,symptom,creatinkinase,ECG and coronary arteriongraphy(CAG).There were 66 patients with acute coronary syndromes and 11 patients with stable angina pectoris.12 health persons were choosed as normal control.Blood samples of patients were collected in 24 hours after admission.The peripheral blood levels of MPO and NT-proBNP were measured with enzyme-linked immunosorbent assay(ELISA).All patients were followed up during 90 days and 6 months.Cardiovasular events during observation were recorded.The incidence of cardiovascular events in different groups were compared.All results were analyzed with SPSS 13.0.Results:(1)The peripheral blood levels of MPO were higher in ACS group than in control group,P<0.05;compared ACS group with SAP group,P<0.05;compared SAP group with control group,P>0.05.(2)The peripheral blood levels of NT-proBNP were higher in ACS group than in control group,P<0.05;compared ACS group with SAP group,P<0.05;compared SAP group with control group,P<0.05.(3)The incidence of cardiovascular events during 90 days and 6 months increased when the levels of MPO or NT-proBNP were high.(4)When the levels of MPO and NT-proBNP were combined,the incidence of cardiovascular events in patients with high levels of MPO and NT-proBNP was the highest among the four groups(P<0.05).Conclusions:(1)Either MPO or NT-proBNP can predict the short term prognosis of patients with ACS.(2)The combined detection of peripheral blood levels of MPO and NT-proBNP can have the most significant clinical value in predicting the short term prognosis of patients with ACS.
|
PDF Full Text Request